-
1.RISK ASSESSMENT FOR CUTANEOUS ADVERSE DRUG REACTIONS FROM ANTIRETROVIRAL AGENT 有权
标题翻译: 抗逆转录病毒药物不良反应的风险评估公开(公告)号:US20110301043A1
公开(公告)日:2011-12-08
申请号:US13133520
申请日:2009-12-11
申请人: Somnuek Sungkanuparph , Sasisopin Kiertiburanakul , Thanyachai Sura , Wasun Chantratita , Soranun Chantarangsu , Angkana Charoenyingwattana , Surakameth Mahasirimongkol , Michiaki Kubo , Taisei Mushiroda , Yusuke Nakamura
发明人: Somnuek Sungkanuparph , Sasisopin Kiertiburanakul , Thanyachai Sura , Wasun Chantratita , Soranun Chantarangsu , Angkana Charoenyingwattana , Surakameth Mahasirimongkol , Michiaki Kubo , Taisei Mushiroda , Yusuke Nakamura
CPC分类号: G01N33/6893 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , G01N33/94 , G01N33/9493 , G01N2800/20 , G01N2800/50
摘要: The present invention provides a method of predicting the risk of a patient for developing cutaneous adverse drug reaction to non-nucleoside reverse transcriptase inhibitors such as nevirapine by using HLA-B*3505 allele and/or polymorphisms in the CCHCR1 gene.
摘要翻译: 本发明提供一种通过使用CCHCR1基因中的HLA-B * 3505等位基因和/或多态性来预测患者对非核苷逆转录酶抑制剂如奈韦拉平发生皮肤不良药物反应的风险的方法。
-
2.Risk assessment for cutaneous adverse drug reactions from antiretroviral agent 有权
标题翻译: 抗逆转录病毒药物对皮肤药物不良反应的风险评估公开(公告)号:US09557341B2
公开(公告)日:2017-01-31
申请号:US13133520
申请日:2009-12-11
申请人: Somnuek Sungkanuparph , Sasisopin Kiertiburanakul , Thanyachai Sura , Wasun Chantratita , Soranun Chantarangsu , Angkana Charoenyingwattana , Surakameth Mahasirimongkol , Michiaki Kubo , Taisei Mushiroda , Yusuke Nakamura
发明人: Somnuek Sungkanuparph , Sasisopin Kiertiburanakul , Thanyachai Sura , Wasun Chantratita , Soranun Chantarangsu , Angkana Charoenyingwattana , Surakameth Mahasirimongkol , Michiaki Kubo , Taisei Mushiroda , Yusuke Nakamura
CPC分类号: G01N33/6893 , C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , G01N33/94 , G01N33/9493 , G01N2800/20 , G01N2800/50
摘要: The present invention provides a method of predicting the risk of a patient for developing cutaneous adverse drug reaction to non-nucleoside reverse transcriptase inhibitors such as nevirapine by using HLA-B*3505 allele and/or polymorphisms in the CCHCR1 gene.
摘要翻译: 本发明提供一种通过使用CCHCR1基因中的HLA-B * 3505等位基因和/或多态性来预测患者对非核苷逆转录酶抑制剂如奈韦拉平发生皮肤不良药物反应的风险的方法。
-